Sarcoid-like reaction and hypothyroidism induced by PD-1 inhibitor treatment in metastatic renal cell carcinoma: a case report and literature review

被引：2

作者：

Shrateh, Oadi N. ^{[1
]}

Abugharbieh, Yazan ^{[2
]}

Abu Asbeh, Yousef ^{[3
]}

Hour, Hani ^{[4
]}

Awad, Iyad ^{[2
]}

Bannoura, Sami ^{[5
]}

机构：

[1] Al Quds Univ, Fac Med, Jerusalem, Palestine

[2] Al Ahli Hosp, Deparment Radiol, Hebron, Palestine

[3] Al Ahli Hosp, Dept Thorac Surg, Hebron, Palestine

[4] Al Ahli Hosp, Dept Oncol, Hebron, Palestine

[5] Al Ahli Hosp, Dept Pathol, Hebron, Palestine

来源：

BMC PULMONARY MEDICINE | 2024年 / 24卷 / 01期

关键词：

Renal cell carcinoma; Pembrolizumab; Sarcoid like reaction; Hypothyroidism; PEMBROLIZUMAB; CANCER; EPIDEMIOLOGY; NEPHRECTOMY; SUNITINIB; SURVIVAL;

D O I：

10.1186/s12890-024-02943-9

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

BackgroundPembrolizumab is among the approved treatments for a variety of cancer types, including clear cell renal cell carcinoma (ccRCC). It has contributed to enhancing the prognosis of renal cell carcinoma. However, it is essential to be aware of the numerous potential immune-related side effects associated with its use.Case presentationA 69-year-old patient with a history of metastatic renal cell carcinoma has been undergoing treatment with Pembrolizumab, an immune checkpoint inhibitor. The medication has led to the development of a sarcoid-like reaction, initially misinterpreted as cancer recurrence and progression. Additionally, the patient has experienced new-onset hypothyroidism, which has been attributed to the immunotherapy.ConclusionClinicians, including oncologists, endocrinologists, and radiologists, should maintain a high level of suspicions and awareness regarding the potential adverse events associated with newly introduced immunotherapies like pembrolizumab. This knowledge is crucial for the accurate diagnosis and appropriate management of patients receiving these treatments.

引用

页数：8

共 48 条

[1] Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer [J].

Agrawal, Sundeep ;

Haas, Naomi B. ;

Bagheri, Mohammadhadi ;

Lane, Brian R. ;

Coleman, Jonathan ;

Hammers, Hans ;

Bratslavsky, Gennady ;

Chauhan, Cynthia ;

Kim, Lauren ;

Krishnasamy, Venkatesh P. ;

Marko, Jamie ;

Maher, Virginia Ellen ;

Ibrahim, Amna ;

Cross, Frank ;

Liu, Ke ;

Beaver, Julia A. ;

Pazdur, Richard ;

Blumenthal, Gideon M. ;

Singh, Harpreet ;

Plimack, Elizabeth R. ;

Choueiri, Toni K. ;

Uzzo, Robert ;

Apolo, Andrea B. .

JAMA ONCOLOGY, 2020, 6 (01) :133-141

[2] PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome [J].

Alsaab, Hashem O. ;

Sau, Samaresh ;

Alzhrani, Rami ;

Tatiparti, Katyayani ;

Bhise, Ketki ;

Kashaw, Sushil K. ;

Iyer, Arun K. .

FRONTIERS IN PHARMACOLOGY, 2017, 8

[3] Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma [J].

Cheshire, Sophie C. ;

Board, Roth E. ;

Lewis, Alexandra R. ;

Gudur, Laxminarayan D. ;

Dobson, Michael J. .

RADIOLOGY, 2018, 289 (02) :564-567

[4] Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Tomczak, P. ;

Park, S. H. ;

Venugopal, B. ;

Ferguson, T. ;

Chang, Y. -H. ;

Hajek, J. ;

Symeonides, S. N. ;

Lee, J. L. ;

Sarwar, N. ;

Thiery-Vuillemin, A. ;

Gross-Goupil, M. ;

Mahave, M. ;

Haas, N. B. ;

Sawrycki, P. ;

Gurney, H. ;

Chevreau, C. ;

Melichar, B. ;

Kopyltsov, E. ;

Alva, A. ;

Burke, J. M. ;

Doshi, G. ;

Topart, D. ;

Oudard, S. ;

Hammers, H. ;

Kitamura, H. ;

Bedke, J. ;

Perini, R. F. ;

Zhang, P. ;

Imai, K. ;

Willemann-Rogerio, J. ;

Quinn, D. I. ;

Powles, T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (08) :683-694

[5] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[6] Systemic Therapy for Metastatic Renal-Cell Carcinoma [J].

Choueiri, Toni K. ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04) :354-366

[7] Epidemiology and risk factors for kidney cancer [J].

Chow, Wong-Ho ;

Dong, Linda M. ;

Devesa, Susan S. .

NATURE REVIEWS UROLOGY, 2010, 7 (05) :245-257

[8] Seven years after laparoscopic radical nephrectomy: Oncologic and renal functional outcomes [J].

Colombo, Jose R., Jr. ;

Haber, Georges-Pascal ;

Jelovsek, John E. ;

Lane, Brian ;

Novick, Andrew C. ;

Gill, Inderbir S. .

UROLOGY, 2008, 71 (06) :1149-1154

[9] Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation [J].

Correa, Andres F. ;

Jegede, Opeyemi ;

Haas, Naomi B. ;

Flaherty, Keith T. ;

Pins, Michael R. ;

Messing, Edward M. ;

Manola, Judith ;

Wood, Christopher G. ;

Kane, Christopher J. ;

Jewett, Michael A. S. ;

Dutcher, Janice P. ;

DiPaola, Robert S. ;

Carducci, Michael A. ;

Uzzo, Robert G. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (23) :2062-+

[10]

Cotliar Jonathan, 2016, JAAD Case Rep, V2, P290, DOI 10.1016/j.jdcr.2016.06.004

← 1 2 3 4 5 →